Portola Pharma Raises $60 million

Portola Pharmaceuticals Inc. raised $60 million in Series C financing led by D.E. Shaw. Further investors include Abingworth Management, Advanced Technology Ventures, AllianceBernstein, Alta Partners, Brookside Capital, CIDC Consulting, Frazier Healthcare Ventures, Goldman Sachs, IBT Management Corp., MPM Capital, Prospect Venture Partners, Sutter Hill Ventures, Teachers’ Private Capital and T. Rowe Price, and new investors, Adage Capital Management, Apothecary Capital, Janus Capital and PAC-Link BioVentures. Portolo, based in San Francisco, is developing two cardiovascular drugs which may be ready for Phase III trials in 2010.